Bottom line
Is PXSAX a good fund? The bottom line
PXSAX is the Class A share class of Impax Small Cap Fund, a managed small-cap mutual fund from Impax I.
It charges 1.16% — about $116 a year on every $10,000 invested, more expensive than 66% of small-cap funds we track.
It returned +11.5% over one year, +7.8% a year over five years, +8.0% a year over ten (as of Dec 31, 2025, per its prospectus).
With $949 million in net assets and 62 holdings, its largest position is Ligand Pharmaceuticals, Inc. (5.1%) and the top 10 make up 30.7% of the portfolio.
This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.
What to watch
- Front-end sales load up to 5.5%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What PXSAX invests in
The Small Cap Funds investment objective is to seek long-term growth of capital.
The Small Cap Fund follows a sustainable investing approach, investing in companies that the Adviser believes are well positioned to benefit from the transition to a more sustainable global economy, integrating a proprietary corporate resilience (Corporate Resilience) (formerly known as ESG) analysis that considers governance structures, the management of material environmental and social risks, climate risks (physical and transition), human capital management, and controversies (such analysis, Corporate Resilience Analysis) into portfolio construction and managing the portfolio within certain risk parameters (e.g., sector and regional exposure) relative to the Funds benchmark universe of Russell 2000 Index companies. The Fund utilizes the Impax Sustainability Lens, a proprietary tool designed to facilitate a systematic review of the economic opportunities and risks associated with the…
From the fund's prospectus (filed Apr 24, 2026).
PXSAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| PXSAX | +11.5% | +7.8% | +8.0% |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2025
What PXSAX costs
On a $10,000 investment, PXSAX's 1.16% expense ratio costs about $116 a year. The prospectus estimates $1,881 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
PXSAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Ligand Pharmaceuticals, Inc. | 5.08% |
| 2 | Victory Capital Holdings, Inc. | 4.65% |
| 3 | Eastern Bankshares, Inc. | 2.99% |
| 4 | Mitek Systems, Inc. | 2.88% |
| 5 | Neurocrine Biosciences, Inc. | 2.84% |
| 6 | Acadian Asset Management, Inc. | 2.64% |
| 7 | Teradata Corp. | 2.50% |
| 8 | SI-BONE, Inc. | 2.45% |
| 9 | Onto Innovation, Inc. | 2.35% |
| 10 | Pinnacle Financial Partners, Inc. | 2.29% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 30.7% of the fund. See all top 25 holdings and asset mix →